Payment overview · 2025
General Payments
$729.66
31 reported records · 16 companies
Healthcare provider profile · identity verified
Mackenzie Hoffman, DNP AGNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · EDEN, NC · NPI 1821641002
Verified facts
What the public records show
CMS Open Payments records show Mackenzie Hoffman, DNP AGNP received $729.66 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.02 | 19.1% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $114.88 | 15.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.37 | 13.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.07 | 7.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.28 | 7.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.02 | 6.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.83 | 5.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.14 | 5.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $27.04 | 3.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.75 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.18 | 2.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.93 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.08 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.94 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.66 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $114.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $91.86 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $88.42 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.35 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.07 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.02 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 211 | 141 |
| Gabapentin | Gabapentin | 193 | 41 |
| Metformin Hcl | Metformin Hcl | 182 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 38 |
| Alprazolam | Alprazolam | 156 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 42 |
| Lisinopril | Lisinopril | 132 | 33 |
| Tramadol Hcl | Tramadol Hcl | 110 | 28 |
| Losartan Potassium | Losartan Potassium | 108 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 16 |
| Furosemide | Furosemide | 64 | 19 |
| Buspirone Hcl | Buspirone Hcl | 62 | 15 |
| Omeprazole | Omeprazole | 62 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 48 |
| Glipizide Er | Glipizide | 60 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 29 |
| Trazodone Hcl | Trazodone Hcl | 58 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 13 |
| Potassium Chloride | Potassium Chloride | 55 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 20 |
| Jardiance | Empagliflozin | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Azithromycin | Azithromycin | 48 | 43 |
| Montelukast Sodium | Montelukast Sodium | 47 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 40 |
| Atenolol | Atenolol | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Simvastatin | Simvastatin | 44 | 12 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Diazepam | Diazepam | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Cephalexin | Cephalexin | 21 | 19 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.66 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OMNIPOD, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, YUPELRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error